NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 12 metastatic midgut neuroendocrine tumours (NETs). The results to date showed 177Lu-DOTATATE provided a clinically meaningful and statistically significant increase in progression-free survival (PFS) in the patients treated with 177Lu-DOTATATE.
Presented at the European Cancer Conference (ECC) 2015 by Philippe Ruszniewski, MD, of Beaujon Hospital, Clichy, France
European Medical Journal
Advertisement
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews